NEW YORK (GenomeWeb) – N-of-One said today that it will provide clinical interpretation services to Intermountain Healthcare as part of the hospital system's oncology precision medicine services program.
Under the terms of the agreement, N-of-One will handle the interpretation of cancer patients' next-generation sequencing test results. Using its platform, the firm will link relevant biological and clinical knowledge to the mutation profiles of tumors and help oncologists identify more effective therapeutic strategies for their patients.
Intermountain tapped N-of-One's service for its tumor test offering because of the firm's "oncology domain expertise combined with their flexible and efficient delivery capabilities," Lincoln Nadauld, director of cancer genomics at Intermountain Healthcare, said in a statement. The interpretation services will enable "us to implement a premier precision medicine program which better serves the needs of a broad range of oncologists and their patients," he said.
Financial terms of the agreement were not disclosed.
Intermountain is a non-profit health system based in Salt Lake City that includes 22 hospitals and around 1,100 primary care and secondary care physicians at more than 185 clinics. Earlier this year, it inked a deal with Syapse to provide oncologists with access to tumor genome profiling, data analysis, and drug procurement services.